Weldon School Distinguished Seminar - Wed., Sept. 21
Event Date: | September 21, 2022 |
---|---|
Hosted By: | Weldon School of Biomedical Engineering |
Time: | 9:30 a.m. |
Location: | MJIS 1001 and via Zoom |
Priority: | No |
School or Program: | Biomedical Engineering |
College Calendar: | Show |
Abstract: Many chronic diseases have a fibroproliferative component that, if untreated, results in replacement of healthy tissue with fibrotic scar leading to organ dysfunction and ultimate failure. Examples include heart failure, chronic kidney diseases like diabetic nephropathy, chronic liver diseases like NASH, idiopathic pulmonary fibrosis, Crohn’s disease, and scleroderma. Cancers like pancreatic ductal adenocarcinoma also have a fibrotic component. Imaging methods for tissue fibrosis are in general deficient and if available are typically only sensitive to advanced disease. Our lab has been developing molecular probes with MRI or PET imaging reporters to address unmet needs across these disease areas. We are using molecular imaging to address unmet needs in early detection of tissue fibrosis, in noninvasive staging of disease, in measuring disease activity to predict disease progression, and in measuring treatment response. We have also been applying molecular imaging to accelerate therapeutic drug development by measuring drug target expression and target engagement. Since molecular imaging is additive, we have developed multimodal and multiparametric methods for tissue characterization. This lecture will provide examples of these molecular probes and their applications in different models of pulmonary, liver, kidney, and heart disease and in early stage clinical trials.
Bio: Peter Caravan, PhD, is co-director of the Institute for Innovation in Imaging (i3) at Massachusetts General Hospital (MGH) and Professor of Radiology at Harvard Medical School. He leads a multidisciplinary and translational molecular imaging lab focused on the invention of novel molecular probes and their broad applications in cardiovascular, pulmonary, renal and hepatic diseases, as well as in cancers. His research spans novel chemistry technologies to advanced MRI and PET imaging in animal models to applications in patient populations. A particular area of focus is imaging in fibroproliferative diseases and the development of new imaging tools for early detection of disease and for measuring disease activity in order to guide treatment. He holds Investigational New Drug (IND) applications for a fibrin-targeted PET tracer and a collagen-targeted PET tracer that are currently being evaluated in 8 clinical trials. Dr. Caravan has invented a general purpose gadolinium-free MRI contrast agent that has been out licensed and is currently in clinical development. He has also invented molecular probes specific to fibrogenesis, acidosis, inflammation and thrombosis.
Dr. Caravan received a PhD in Inorganic Chemistry from the University of British Columbia. Following postdoctoral work at the EPFL (Switzerland), he spent 9 years at Epix Pharmaceuticals developing tissue-specific and responsive MRI contrast agents, one of which, gadofosveset, was approved by the FDA and the EMA. He co-founded two companies that are working on commercialization of technology from laboratory. Since joining the MGH in 2007, he has been continuously funded by the NIH.
~BME Faculty Host: Dr. Uzay Emir ~
NOTE: Students registered for the seminar are expected to attend in-person.
Zoom link: https://purdue-edu.zoom.us/j/7731446991?pwd=RHdkZTVnRkxTM3J3dnRvY1VLWTlYUT09
2022-09-21 09:30:00 2022-09-21 10:30:00 America/Indiana/Indianapolis Weldon School Distinguished Seminar - Wed., Sept. 21 Peter Caravan, PhD, Professor of Radiology at Harvard Medical School will present a Distinguished Seminar on Wednesday, September 21, at 9:30 a.m. in MJIS 1001 and via Zoom. The presentation will be entitled "Molecular MR and PET imaging in fibroproliferative diseases." MJIS 1001 and via Zoom